NANOMICRO(688690)2024-12-26 10:11Business Growth Opportunities - The company has significant growth opportunities in the GLP-1 class peptide drug applications, with rapid revenue growth in this area over the past two years [1] - The company is optimizing product performance to enable domestic chromatographic filler replacements without changing purification process conditions [1] - The current focus is primarily on injectable drug formulations, with potential for further market expansion if oral drugs achieve mass production [1] Customer Considerations for Filler Suppliers - For macromolecule customers, key factors include a complete quality management system, reliable production and supply capabilities, and competitive pricing [1] - For small molecule customers, suppliers must provide improved separation and purification processes to meet green production trends and market competition pressures [1] Investor Relations Activities - The company held a meeting with investors on December 25, 2024, to discuss performance, management, product development, market expansion, and team integration [1] - Participants included representatives from Tianfeng Securities, Fullgoal Fund, Soochow Securities, Bank of China, Orient Red, Morgan, and Shenwan Lingxin [1]